Premier Biomedical (BIEI) Stock Price, News & Analysis

Company Overview

Premier Biomedical, Inc. (OTCMKTS: BIEI) is a U.S.-based biotechnology company focused on the research, development and commercialization of targeted therapies and diagnostic solutions. The company’s core activities center on immuno-oncology and precision medicine, leveraging proprietary platform technologies to engineer novel monoclonal antibodies, cell-based immunotherapies and companion diagnostics. Premier Biomedical’s pipeline encompasses both therapeutic candidates and assay kits designed to enhance patient stratification and treatment efficacy for a range of cancer indications.

Since its founding in 2002, Premier Biomedical has pursued a dual strategy of internal research and strategic collaborations. Its proprietary XCell platform enables high-throughput screening of antibody fragments and synthetic peptides, while its CellMap diagnostics line offers molecular profiling tools for clinical laboratories. The company’s research team is advancing several preclinical candidates, including targeted antibody–drug conjugates and adoptive cell therapies, with the goal of initiating early-stage clinical trials in the coming years.

Premier Biomedical operates primarily in North America and Europe, partnering with contract research organizations, academic centers and biopharmaceutical firms to accelerate development and expand market access. The company’s manufacturing and quality control facilities are located in New Jersey, with distribution channels that extend to strategic markets in Germany and the United Kingdom. These collaborations support both in-house pipeline advancement and out-licensing opportunities for select technologies.

Led by President and Chief Executive Officer Dr. John Brenner, Premier Biomedical’s management team brings decades of experience in drug discovery, regulatory affairs and commercial development. The board includes senior executives from leading biotech and healthcare enterprises, underscoring the company’s commitment to rigorous governance and scientific innovation. As Premier Biomedical continues to build its portfolio, it remains focused on delivering differentiated therapies and diagnostic solutions that address unmet clinical needs.

Key Stats

• Today's Range: $0.0005 to $0.0006
• 50-Day Range: N/A
• 52-Week Range: $0.0003 to $0.0021
• Volume: 2.59 million shs
• Average Volume: 5.96 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIEI Stock Analysis - Frequently Asked Questions

How have BIEI shares performed this year?

Premier Biomedical's stock was trading at $0.0007 at the beginning of 2025. Since then, BIEI stock has decreased by 14.3% and is now trading at $0.0006.

How do I buy shares of Premier Biomedical?

Shares of BIEI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Premier Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Premier Biomedical investors own include Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), CytoDyn (CYDY), Vaxart (VXRT), Arcturus Therapeutics (ARCT) and Actinium Pharmaceuticals (ATNM).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BIEI
• CIK: 1515740
• Web: www.premierbiomedical.com
• Phone: 724-633-7033
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A